AGS Therapeutics, based in Paris and Genopole (www.genopole.fr), Evry, France, is a biotech company pioneering the use of microalgae extracellular vesicles (MEVs) as a universal delivery system for innovative biologics, vaccines and gene therapies. AGS has shown MEVs to be a safe, targeted and highly versatile delivery system for mRNA, siRNA, DNA oligos, plasmids, proteins, and peptides relevant to a broad range of human diseases.
AGS Therapeutics has two lead therapeutic candidates in development, both addressing multi-billion markets with significant unmet needs:
• AGS-1010 for wet age-related macular degeneration (wAMD), with a potential breakthrough in topical administration (eye drops) that could significantly improve patient comfort and compliance compared to current standard-of-care (injections into the eye).
• AGS-2010 for inflammatory bowel disease (IBD), offering a non-systemic oral treatment option.
AGS-M, the company’s CDMO subsidiary, produces the MEVs needed to support R&D from AGS and from companies partnering with AGS. AGS’ MEVs are derived from Chlorella, a two-billion-year-old single-cell algae, labelled by the FDA as GRAS for consumption as a food supplement. AGS’ MEVs are easy to manufacture in large quantities with processes that are both eco-friendly and easily scalable. Through strategic partnerships and a commitment to scientific excellence, the company aims to challAGS-M, a contract development and manufacturing organization, produces the MEVs needed to support preclinical and clinical development of MEV-based product pipelines from AGS Therapeutics, and from pharmaceutical and other companies partnering with AGS.
AGS’ MEVs are derived from Chlorella, a 2-billion-year-old single-cell algae used for decades as a food supplement. AGS’ MEVs are easy to manufacture in large quantities with simple cell culture media production techniques that are both eco-friendly and easily scalable. For more information visit www.ags-tx.com and www.ags-m.com.
Company Details
- Employees
- 10
- Founded
- -
- Address
- 10, Rue Greneta, Paris,île-De-France 75003,france
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://ags-tx.com/
- Keywords
- Oxford.
- HQ
- Paris, Île-de-France
Ags Therapeutics Questions
Ags Therapeutics's website is https://ags-tx.com/
Ags Therapeutics's LinkedIn profile is https://fr.linkedin.com/company/ags-tx
Ags Therapeutics has
10 employees.
View email and phone details for 10
employees at Ags Therapeutics.
Ags Therapeutics's industry is
Biotechnology Research
Ags Therapeutics's top competitors are
Evox Therapeutics Ltd,
Acticor Biotech,
Aken Medical,
Aegle Therapeutics,
Endogene.bio,
Abcell-Bio,
Proteme,
Abivax,
Cell Environment,
Silica Corpora.
Ags Therapeutics's categories are Biotechnology Research
Ags Therapeutics's founding year is 2020
